Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)
1 other identifier
interventional
239
1 country
1
Brief Summary
Comparing different method of surgical technique D2 lymph node dissection vs D3 for right colon cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 25, 2017
CompletedFirst Submitted
Initial submission to the registry
March 25, 2017
CompletedFirst Posted
Study publicly available on registry
June 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 3, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 3, 2029
March 26, 2025
March 1, 2025
11.9 years
March 25, 2017
March 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
5-year survival
death from any cause
Up to 5 years post-operative
Secondary Outcomes (3)
morbidity
within the first 30 days after surgery
mortality
within the first 30 days after surgery
Disease free survival 5 years after initial surgery
Up to 5 years post-operative
Study Arms (2)
D2 lymph node dissection for right colon cancer
ACTIVE COMPARATORHemicolectomy for right colon cancer with D2 lymph node dissection
D3 lymph node dissection for right colon cancer
EXPERIMENTALHemicolectomy for right colon cancer with D3 lymph node dissection
Interventions
Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
Eligibility Criteria
You may qualify if:
- Agreement of the patient to participate in trial
- Colon cancer (only adenocarcinoma )
- The tumor located between the cecum and the right 1/3 of transverse colon
- Tumors T3,Т4а,b N0-2 (II-III stages)
- Tolerance of chemotherapy
- ECOG 0-2
You may not qualify if:
- Patients with distant metastases
- Tumors T1-2 (I stage)
- Complications of tumor (perforation and full bowel obstruction)
- Previous radiotherapy or chemotherapy
- Synchronous or metachronous tumors
- Women during Pregnancy or breast feeding period
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
G.V. Bondar Republican Cancer Center
Donetsk, Ukraine
Related Publications (1)
Balaban V, Mutyk M, Bondarenko N, Zolotukhin S, Sovpel O, Sovpel I, Zykov D, Rublevskiy I, Klochkov M, Prado AP, He M, Tsarkov P. Comparison of D2 vs D3 lymph node dissection for RIght COloN cancer (RICON): study protocol for an international multicenter open-label randomized controlled trial. Trials. 2024 Jul 2;25(1):438. doi: 10.1186/s13063-024-08269-5.
PMID: 38956698DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Vladimir Balaban, PhD
M.Gorky Donetsk National Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 25, 2017
First Posted
June 27, 2017
Study Start
January 25, 2017
Primary Completion (Estimated)
January 3, 2029
Study Completion (Estimated)
January 3, 2029
Last Updated
March 26, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share